OncoMatch/Clinical Trials/NCT04472767
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Is NCT04472767 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Ipilimumab for hepatocellular carcinoma.
Treatment: Nivolumab · Ipilimumab · Cabozantinib — This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Any type of previous systemic anti-cancer treatment
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib
Cannot have received: cytotoxic, biologic or other systemic anticancer therapy including investigational agents
Has received prior cytotoxic, biologic or other systemic anticancer therapy including investigational agents within 4 weeks prior to randomization
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Lab requirements
Blood counts
Leukocytes ≥ 2,000/mcL; absolute neutrophil count ≥ 1000/mcL; platelets ≥ 60,000/mcl; hemoglobin ≥ 8 g/dL
Kidney function
creatinine <1.5ULN; Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg
Liver function
total bilirubin within normal institutional limits; AST(SGOT)/ALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present; Serum albumin ≥ 2.8 g/dL
Cardiac function
Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment
Adequate organ and marrow function as defined below: Leukocytes ≥ 2,000/mcL; absolute neutrophil count ≥ 1000/mcL; platelets ≥ 60,000/mcl; total bilirubin within normal institutional limits; AST(SGOT)/ALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present; creatinine <1.5ULN; hemoglobin ≥ 8 g/dL; Serum albumin ≥ 2.8 g/dL; Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg; Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify